FORM 6-K

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer Pursuant to Rule 13a - 16 under the Securities Exchange Act of 1934

For the quarterly period ended November 30, 2004

ICON plc
(Registrant's name)

0-29714 (Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland. (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes X No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes No >

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes No X

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule  $12g3-2(b):82\ N/A$ 

Other Events.

The registrant hereby incorporates by reference the press release attached hereto as Exhibit 99.1 into this report.

## Financial Statements and Exhibits.

(c) The following Exhibits are filed as part of this report:

EXHIBIT NO. DESCRIPTION

99.1 Press Release

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ICON plc

January 6, 2005	/s/ Sean Leech	
ate	Sean Leech Chief Financial Officer	

ICON reports a 9% increase in net revenues, EPS of \$0.41 and net new business awards of \$120 million for the Second Quarter FY 2005 (NASDAQ:ICLR)

Highlights - Second Quarter Fiscal 2005

- \* Second quarter net revenues increased 9% over the second quarter of fiscal 2004 to \$79.5 million and increased 11% on a year-to-date basis.
- \* Income from operations decreased 16% over the second quarter of fiscal 2004 to \$7.0 million and increased 3% in the six months to November 30, 2004.
- \* Diluted earnings per share decreased 9% for the second quarter to 41 cents compared to 45 cents in same quarter last year. Year-to-date diluted earnings per share was 93 cents compared to 92 cents for the comparable period last year.
- \* \$120 million of net new business awarded to ICON during the quarter.

Dublin, Ireland, January 6, 2005 - ICON plc (NASDAQ: ICLR), a global contract clinical research organisation, which has approximately 2,600 employees providing services to the pharmaceutical, biotech and medical device industries from 37 locations in 23 countries worldwide, today reported the financial results for its second quarter ended November 30, 2004.

Net revenues for the quarter were \$79.5 million, representing a 9% increase over net revenues of \$73.2 million for the same quarter last year. Excluding the impact of acquisitions, revenue growth for the quarter was 6% over the same quarter last year.

Income from operations for the quarter was \$7.0 million, which represents a decrease of 16% from the \$8.4 million reported for the second quarter last year. Operating margin for the quarter was 8.8% compared with 11.4% for the equivalent period last year. Net income for the quarter was \$5.8 million or 41 cents per share, on a diluted basis, compared with \$6.3 million or 45 cents per share for the second quarter last year.

In the six months to November 30, 2004, net revenues were \$157.8 million, representing an 11% increase over net revenues of \$142.1 million reported for the first six months of last year. Excluding the impact of acquisitions, revenue growth was 7% for the six months ending November 30, 2004.

Income from operations for the six months to November 30, 2004 was \$16.5 million, representing an increase of 3% from the \$16.0 million reported for the same period last year. Operating margin for the six months to November 30, 2004 was 10.4%, compared with 11.2% in the same period last year. Net income was \$13.1 million or 93 cents per share, on a diluted basis compared with \$11.9 million or 92 cents per share reported for the same period last year.

Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 69 days at November 30, 2004 compared with 60 days at May 31, 2004.

Capital expenditure in the quarter ended November 30, 2004, was \$2.9 million and year to date was \$7.5 million. As a result, the company's net cash, short-term debt and short-term investments were \$61.0 million at November 30, 2004, compared to \$65.6 million at August 31, 2004 and \$78.8 million at May 31, 2004.

"The quarter ended November 30, 2004 was the first quarter in over 5 years in which our earnings declined, but was in line with our expectations following the exceptionally high level of cancellations we suffered in the previous quarter", commented Chairman, Dr John Climax. " As predicted, this high cancellation experience appears to have been an anomaly. With strong gross wins of \$122 million, and cancellations of only \$2 million in our most recent quarter, we believe we have a solid foundation for a return to growth in Fiscal 2006 although we will need

further quarters of solid business wins to consolidate this. Nevertheless we are revising our EPS guidance for Fiscal 2005 to between \$1.68 - \$1.70. The rationale for this revision will be discussed in more detail on our conference call today"

The company will hold its second quarter conference call today, January 6, 2005 at 8:00 EST [13:00 GMT / 14:00 CET]. This call and linked slide presentation can be accessed live from our website at http://www.iconclinical.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "shareholders services". This calendar will be updated regularly.

The statements made in this Press Release may contain forward-looking statements

that involve a number of risks and uncertainties. In addition to the matters described in this Press Release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

The financial information presented herein has been prepared in accordance with  $\mbox{U.S. }\mbox{GAAP.}$ 

Source: ICON plc

Contact : Investor Relations 1-888-381-7923 or Sean Leech CFO + 353 -1-291-2000

Both at ICON.

http://www.iconclinical.com

## ICON plc

# Consolidated Income Statements (Unaudited)

Three and Six Months ended November 30, 2004 and 2003 (Dollars, in thousands, except share and per share data)

	Three Month November 30, 2004	ns Ended November 30, 2003	Six Months November 30, 2004	Ended November 30, 2003
Gross Revenue	117,068	113,173	234,263	219,350
Subcontractor costs	37,573	39,966	76,429	77,208
Net Revenue		73,207	157,834	142,142
Costs and expenses Direct costs Selling, general and administrative Depreciation and amortization		40,070 22,041 2,732	86,124 48,859 6,358	43,066
Total costs and expenses	72,487		141,341	
Income from operations	7,008	8,364	16,493	15,986
Interest income (net)	179	75	343	122
Income before provision of income taxes		8,439	16,836	
Provision for income taxes Minority Interest	1,310 58	2,174	3,632 80	4,239
Net income	5,819	6,265	13,124 ====================================	11,869
Net income per ordinary share Basic	\$0.42	\$0.46	\$0.95	\$0.96
Diluted	\$0.41	\$0.45	\$0.93	\$0.92
Weighted average number of ordinary shares Basic	13,847,689	13,578,859	13,839,857	12,346,147
Diluted	14,067,079	14,040,419	14,088,030	12,849,374

ICON plc

## Summary Balance Sheet Data November 30, 2004 and May 31, 2004 (Dollars, in thousands)

November 30,

May 31, 2004 2004 (unaudited) (audited) Cash and short-term investments 71,020 78,763 (10,000) 61,020 Short-term debt 78,763 Net cash Accounts receivable 91,324 74,079 Unbilled revenue 71,246 59,861 Payments on account (74, 186)(61,960)88,384 71,980 Total Working Capital 120,020 113,813

Source: ICON plc

Total assets

Shareholder's equity

Contact: Investor Relations 1-888-381-7923 or

Sean Leech CFO + 353 1 291 2000

370,369

236,254

335,323

216,760

both at ICON.

http://www.iconclinical.com